{"id":508800,"date":"2020-09-28T13:54:01","date_gmt":"2020-09-28T13:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=508800"},"modified":"2020-09-28T13:54:01","modified_gmt":"2020-09-28T13:54:01","slug":"hyperuricemia-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hyperuricemia-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_508800.html","title":{"rendered":"Hyperuricemia Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hyperuricemia Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Hyperuricemia Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Hyperuricemia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, US) DelveInsight has launched a new report on <strong>&#8220;Hyperuricemia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong>&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hyperuricemia-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">Hyperuricemia &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/a>&#8221;&nbsp;<\/strong>report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The most recent significant study of hyperuricemia and gout found that 43.3 million Americans have the condition.<\/li>\n<li>The&nbsp;prevalence&nbsp;rate of&nbsp;hyperuricemia&nbsp;in the general population is estimated at 20-25%, but only 4-6% in premenopausal women<\/li>\n<li>The&nbsp;prevalence&nbsp;of gout is 5.9% in men and 2% in women.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperuricemia-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hyperuricemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Hyperuricemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Hyperuricemia epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Hyperuricemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Hyperuricemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hyperuricemia market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hyperuricemia-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\"><strong>Hyperuricemia<\/strong><\/a> occurs when there&rsquo;s too much uric acid in your blood. High uric acid levels can lead to several diseases, including a painful type of arthritis called gout. Elevated uric acid levels are also associated with health conditions such as heart disease, diabetes, and kidney disease.<\/p>\n<p style=\"text-align: justify;\">Uric acid is formed when purines break down in your body. Purines are chemicals found in certain foods. This typically includes:<\/p>\n<ul style=\"text-align: justify;\">\n<li>red meat<\/li>\n<li>organ meat<\/li>\n<li>seafood<\/li>\n<li>beans<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Normally, your body rids itself of uric acid when you urinate. Hyperuricemia occurs when your body either makes too much uric acid or is unable to excrete enough of it. It usually happens because your kidneys aren&rsquo;t eliminating it quickly enough.<\/p>\n<p style=\"text-align: justify;\">Excess uric acid levels in your blood can lead to the formation of crystals. Although these can form anywhere in the body, they tend to form in and around your joints and in your kidneys. Your body&rsquo;s defensive white blood cells may attack the crystals, causing inflammation and pain.<\/p>\n<p style=\"text-align: justify;\">Rates of hyperuricemia have risen sharply since 1960.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperuricemia-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hyperuricemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The major players covered in the&nbsp;hyperuricemia drugs market&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Takeda Pharmaceutical Company Limited<\/li>\n<li>Mylan N.V.<\/li>\n<li>Sun Pharmaceutical Industries Limited<\/li>\n<li>Hikma Pharmaceutical PLC<\/li>\n<li>Dr. Reddy&rsquo;s Laboratories Ltd<\/li>\n<li>Sanofi<\/li>\n<li>Sandoz AG<\/li>\n<li>Amneal Pharmaceuticals LLC<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperuricemia-market?utm_source=Pressrelease&amp;utm_medium=Pressrelease&amp;utm_campaign=Pressrelease\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hyperuricemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Hyperuricemia<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Competitive Intelligence Analysis for Hyperuricemia<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Hyperuricemia: Market Overview at a Glance<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Hyperuricemia Total Market Share (%) Distribution in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Hyperuricemia Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\"><strong>5. Hyperuricemia: Disease Background and Overview<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2. Sign and Symptoms&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3. Pathophysiology&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4. Risk Factors&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5. Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>6. Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Hyperuricemia Epidemiology and Patient Population<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Hyperuricemia Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Hyperuricemia Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.1.1. Hyperuricemia Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.2.1. Hyperuricemia Epidemiology Scenario in France (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.3.1. Hyperuricemia Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.4.1. Hyperuricemia Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.5.1. Hyperuricemia Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.6.1. Hyperuricemia Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><strong>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1. Hyperuricemia Treatment and Management<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2. Hyperuricemia Treatment Algorithm&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>9. Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Key Endpoints of Hyperuricemia Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Marketed Products<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>12. Emerging Therapies<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>13. Hyperuricemia: Seven Major Market Analysis<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Hyperuricemia Market Size in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. Hyperuricemia Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\"><strong>14. Attribute analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. 7MM: Market Outlook<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.1. Hyperuricemia Total Market Size in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.2. Hyperuricemia Market Size by Therapies in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1. Hyperuricemia Total Market Size in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2. Hyperuricemia Market Size by Therapies in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.1. Hyperuricemia Total Market Size in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.2. Hyperuricemia Market Size by Therapies in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.1. Hyperuricemia Total Market Size in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.2. Hyperuricemia Market Size by Therapies in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.1. Hyperuricemia Total Market Size in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.2. Hyperuricemia Market Size by Therapies in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.1. Hyperuricemia Total Market Size in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.2. Hyperuricemia Market Size by Therapies in the United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.2. Hyperuricemia Total Market Size in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.3. Hyperuricemia Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><strong>16. Access and Reimbursement Overview of Hyperuricemia<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Market Drivers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Market Barriers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>21. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>23. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hyperuricemia-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/hyperuricemia-market?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/hyperuricemia-market?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/hyperuricemia-market?utm_source=Pressrelease&#038;utm_medium=Pressrelease&#038;utm_campaign=Pressrelease\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hyperuricemia-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Hyperuricemia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; (Albany, US) DelveInsight has launched a new report on &#8220;Hyperuricemia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;. &nbsp; DelveInsight&#8217;s &#8220;Hyperuricemia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;&nbsp;report delivers an in-depth understanding of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hyperuricemia-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_508800.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-508800","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=508800"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508800\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=508800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=508800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=508800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}